Background: Rheumatic diseases in children are associated with significant morbidity and poor health-related quality of life (HRQOL). There is no health-related quality of life (HRQOL) scale available specifically for children with less common rheumatic diseases. These diseases share several features with systemic lupus erythematosus (SLE) such as their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL scale developed for pediatric SLE will likely be applicable to children with systemic inflammatory diseases.
Findings:
We adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY©) to Simple Measure of Impact of Illness in Youngsters (SMILY©-Illness) and had it reviewed by pediatric rheumatologists for its appropriateness and cultural suitability. We tested SMILY©-Illness in patients with inflammatory rheumatic diseases and then translated it into 28 languages. Nineteen children (79% female, n=15) and 17 parents participated. The mean age was 12±4 years, with median disease duration of 21 months (1-172 months) . We translated SMILY©-Illness into the following 28 languages: Danish, Dutch, French (France), English (UK), German (Germany), German (Austria), German (Switzerland), Hebrew, Italian, Portuguese (Brazil) , Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish (Argentina), Spanish (Mexico), Spanish (Venezuela), Turkish, Afrikaans, Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian, Japanese, Romanian, Serbian and Xhosa.
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Introduction
In children, chronic rheumatic diseases are associated with significant disease-and treatment-related morbidity, thus impacting their health-related quality of life (HRQOL). There are generic scales available to assess HRQOL in children with rheumatic diseases such as the Pediatric Quality of Life Inventory (PedsQL)-Rheumatology module [1] . But there is no specific health-related quality of life (HRQOL) scale that addresses the impact of the less common rheumatic diseases such as mixed connective tissue disease (MCTD), juvenile dermatomyositis (JDM), systemic sclerosis (SS), Sjögren's syndrome, vasculitides, Behçets, sarcoidosis or systemic arthritis (SJIA).
Simple Measure of the Impact of Lupus Erythematosus in Youngsters©" (SMILEY) is valid in US-English [2] and in Portuguese-for Brazil [3] . SMILEY-US English was validated through a multicenter study in the US [2] . Subjects with SLE completed other gold standards and SLE status measures and psychometric properties were determined [2] . Relationship of HRQOL and changes in disease activity were measured over time [4] . SMILEY US English was further translated and adapted into several languages [2, 5, 6] .
Hypothesis
Systemic Lupus Erythematosus (SLE) and systemic inflammatory diseases share several features such as their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL scale developed for pediatric SLE will be applicable to children with systemic inflammatory diseases. We decided to adapt a tool that is valid in SLE, titled, SMILEY [2] . We will report the: (i) adaptation of SMILEY© to Simple Measure of Impact of Illness in Youngsters (SMILY©-Illness) for use in children with systemic inflammatory diseases such as MCTD, JDM, SS, Sjögren's syndrome, vasculitis and SJIA and preliminary testing in patients; and (ii) translation into different languages. We think this is very important since the systemic rheumatic diseases mentioned above can lead to significant disability which impact HRQOL.
Methods used
Overview in brief (i) We adapted SMILEY to SMILY©-Illness and had it reviewed by pediatric rheumatologists from two centers (RWJMS, HSS) for its appropriateness and cultural suitability, and tested SMILY©-Illness in as small sample. We examined time taken to complete questionnaire, feasibility, and also collected demographic and diseaserelated data. We subsequently translated it into the following 28 languages using professional translators: Danish, Dutch, French (France), English (UK), German (Germany), German (Austria), German (Switzerland), Hebrew, Italian, Portuguese (Brazil) , Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish (Argentina), Spanish (Mexico), Spanish (Venezuela ), Turkish, Afrikaans, Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian, Japanese, Romanian, Serbian and Xhosa. Each translation was reviewed by the pediatric rheumatologist(s) from that country for its applicability and cultural suitability in order to be approved.
Subjects and settings
Children ≤18 years of age diagnosed with the following systemic chronic rheumatic diseases were included: MCTD, JDM, Sjögren's syndrome, Systemic sclerosis/ CREST, Behçets, sarcoidosis and SJIA. The patients who had to have been followed for at least one month, and able to participate in the study as determined by the pediatric rheumatologist, and their parents (or guardians) were recruited from two US pediatric rheumatology practices a . Children were excluded if they were unable to complete the questionnaires, or had a significant co-morbid condition likely to impact HRQOL exclusive of their rheumatic disease (such as an infectious, endocrine, psychiatric, congenital, genetic, neurodegenerative or an oncological process).
Measures used
The 26-item SMILY©-Illness for children <19 years features parallel child self reports and parent reports with responses in the form of a five-step scale with different facial expressions with 5 th grade reading level. The four domains are similar to that of SMILEY and are: Effect on self (5 items), Limitations (8 items), Social (4 items) and Burden of Illness (7 items) . Scoring is also similar to SMILEY, where each item score ranges from 1 to 5 and the total score is transformed to a 1 to 100 scale. Higher scores indicate better HRQOL. If >12 questions are not answered, the SMILY©-Illness cannot be scored. The first two items on current illness status and HRQOL assessment are not included in the domains or calculating the final score. The remaining questions refer the respondent to the previous month.
Additional data
We examined self-esteem using the Piers Harris Self concept scale (SCS) [7, 8] , entitled, "The Way I Feel About Myself." Average scores usually range from 46-60 with higher scores corresponding to better self-concept. We collected data on demographics, ethnicity, co-morbidity, insurance, education; and impact of disease using the PedsQL-Family information form. We recorded the date of disease onset, and the current/prior use of all medication(s). The Hollingshead Socioeconomic scale (SES) score, which takes into account the educational and occupational status of the family members, was calculated using the educational and occupational status of the parents [9] . The scores range from 8 to 66, with higher scores indicating a higher socioeconomic status [9] .
Procedure
Appropriate Institutional Review Board approval was obtained at both sites. Potential subjects were identified at each center through the clinic appointment schedule or during in-patient admissions. Children and parents completed corresponding versions of the 26-item SMILY©-Illness and the SCS. The investigator was available at all times to respond to queries posed by study respondents.
Methods and statistical analysis
Using the SPSS statistical package for Windows (SPSS Inc, Chicago, Illinois versions 20), we performed descriptive analyses on all variables and examined data distribution, and examined instrument scores for ceiling and floor effects. Minimal missing data were handled in accordance with rules for scoring each questionnaire. Feasibility was determined from the percentage of missing values for each item and the distribution of item responses [10] . Spearman's rho correlation was used.
Results
Nineteen children (79% female, n=15) and 17 parents (16 mothers) participated in the study. The mean age was 12±4 years (3-18 years) with median disease duration of 21 months (1-172 months) , and mean self -concept of 50±8 (36-69). Hollingshead socioeconomic score was 47±11 (26-61). Subjects had the following diagnosis: SJIA (n=5, 26%), dermatomyositis (n=4, 21%), systemic sclerosis/CREST syndrome (n=5, 26%), mixed connective tissue disease (n=2, 11%), Behçet's disease (n=1, 5%), sarcoidosis (n=1, 5%), and Sjögren's syndrome (n=1, 5%). Seventeen patients used the English translation and two patients used the Spanish translation. They were of the following ethnicities: White (n=9, 47%), Black (n=3, 16%), Mexican/Latino (n=6, 32%), and Asian (n=1, 5%). The following had major life events (injury/illness-2, change of job-1, unable to pay bills-1, >/=2 events −4). Six children were in preschool-5 th grade, 11 from 6 th grade -11 th grade and 1 was in college. They had the following insurance to cover their standard clinical care: private (n=12, 63%), Medicaid (n=5, 26%), and other (n=1). The subjects were either currently using the following medications or discontinued them: corticosteroids (14/19, 74%), mycophoenolate mofetil (2/19, 11%), cyclosporine (5/19, 26%), cyclophosphamide and/or rituximab (3/19, 16%), hydroxychloroquine (9/19, 47%), azathioprine (1/19), methotrexate (4/19, 21%), and thalidomide (1/19) .
Seventeen parents stated that their child had a health condition. Fourteen patients had an emergency room/ urgent care visit in the last year. Parents reported a mean of 2.5 ±4, median 2.5 missed work-days in the past 30 days. Parents perceived the impact of child's illness on daily routine at work (sometimes, often or almost always) in 10/14 cases, and ability to concentrate at work (sometimes, often or almost always) in 12/14 cases). The conditions (other than rheumatic diseases) mentioned by the subjects were: neurocardiogenic syncope (n=1), and celiac disease (n=1).
Child and parent SMILY scores were highly correlated (Spearman rho 0.7, p <0.05, n=17). Child SMILY score correlated with duration illness (Spearman rho =0.4, NS). We examined the HRQOL scores of patients who had ever used disease modifying anti-rheumatic drugs (DMARDS) versus those had never used DMARDS. The mean SMILY scores were 71±49 (child, n=15) and 66±15 (parent, n=12) for those had had ever used DMARDS. The mean SMILY scores were 49±13 (child, n=2) and 53±20 (parent) for those had had ever used DMARDS.
Feasibility 17 child and 15 parent subjects completed the corresponding reports of SMILY©-illness. Subjects completed SMILY©-Illness in ≤10 minutes and scoring each questionnaire took ≤ 10 minutes. For the child report of SMILY©-Illness, 5 items were omitted out of a total of 442 items (26 items × 17 children) with mean number of items omitted =0.3±0.7 (range 0-2). Two children did not complete any forms. For the parent report of SMILY©-Illness, 19 items were omitted out of a total of 390 items (26 items × 15 parents who completed the scale). Mean number of items omitted =1.3±2.4 (range 0-8). Maximum number omitted was 8 items by one parent.
Means, standard deviations and response range of SMILY©-Illness and other questionnaires
Scores and distribution of SMILY©-Illness, are provided in Table 1 . All the reviewers of SMILY©-Illness approved the content, found it to be valid and relevant, easy to understand and especially liked the responses in the form of faces. The questionnaire has face and content validity ( Table 2 ). Due to small sample size we did not perform calculation for psychometric properties.
Translation process
We had already described the rigorous translation process of SMILEY in previous manuscripts [5, 6] . All the SMILEY translations were adapted to SMILY©-Illness using a professional translation company. Collaborative relationships with the different centers across the world were already set up. The review process was similar to the process we followed for SMILEY translations [5, 6] . From each country, pediatric rheumatologists reviewed the translation and approved them for content and cultural appropriateness for their population. Table 2 details the entire adaptation Table 1 Scale descriptives for child and parent reports of measures of SMILY-Illness process of 28 languages and all the translations are enclosed at the end of this brief report as Additional file 1.
Conclusion
SMILY©-Illness is a brief, easy to administer and score HRQOL scale for children with systemic rheumatic diseases. SMILY©-Illness is suitable for use across different age groups and literacy levels. SMILY©-Illness has good face and content validity based on its process of adaptation, review by multiple pediatric rheumatologists and initial testing. However, further validation in each country is required for the translated and adapted versions. In our population, a significant percentage of children were on immunosuppressive/immunomodulatory medications. Parents appeared to feel the impact of their child's illness on a daily basis. The children's self-concept was only average. The mean total SMILY illness scores were similar in the range of what we found for SMILEY scores in patients with SLE [2] . The lowest scores were found in the domain of "burden of illness" and the highest score indicating better HRQOL was found in the social domain as reported in other studies [2] . As found in the literature, children had higher scores compared to parents [2] . The number of subjects is very small and it would be ideal if the disease types were well distributed. Unfortunately in this sample they are not due to referral bias at the time of the study. Due to the small sample size, we cannot make any definitive conclusions regarding the correlations. Another limitation is that we do not have information regarding the duration of disease prior to diagnosis.
The availability of translations will make recruitment for validation easier since these diseases are rare. SMILY©-Illness with its available translations may be used as useful adjuncts to clinical practice and research, providing valuable insight to the impact of disease on the overall HRQOL of the child.
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